Loading company…
Neuron23 develops precision medicines using data science and genetic insights.
Founded in 2018 in South San Francisco, Neuron23 develops precision medicines using data science and human genetics. Its pipeline includes NEU-411, an LRRK2 inhibitor, and NEU-111, a TYK2 inhibitor. Nancy Stagliano is CEO; co-founders are Adam Knight, Beth Seidenberg and Michael Almstetter. In June 2025, it raised USD 96.5 million in Series B funding, with Acorn Bioventures, HBM Partners, Kleiner Perkins, Blue Owl Capital, Redmile Group, SB Investment Advisers and Westlake Village BioPartners participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in